Revenue Breakdown
Composition ()
No data
Revenue Streams
Jaguar Health Inc (JAGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Human Health, accounting for 96.1% of total sales, equivalent to $2.86M. Another important revenue stream is Animal Health. Understanding this composition is critical for investors evaluating how JAGX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Jaguar Health Inc maintains a gross margin of 82.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -234.77%, while the net margin is -312.94%. These profitability ratios, combined with a Return on Equity (ROE) of -481.02%, provide a clear picture of how effectively JAGX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, JAGX competes directly with industry leaders such as PRFX and AZTR. With a market capitalization of $2.89M, it holds a significant position in the sector. When comparing efficiency, JAGX's gross margin of 82.74% stands against PRFX's N/A and AZTR's N/A. Such benchmarking helps identify whether Jaguar Health Inc is trading at a premium or discount relative to its financial performance.
